Captopril treatment in rats with DEN-induced cirrhosis and hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the leading cause of cancer-related mortality worldwide. Liver cirrhosis is well-established risk factor of HCC development, although prevention of HCC in cirrhosis patients is challenging. By utilizing bioinformatic compound screening based on a clinical HCC-risk-predicitve gene signature, we identified captopril as a potential HCC chemoprevention agent. We tested the drug in rats with diethylnitrosamine (DEN)-induced cirrhosis and HCC, and confirmed its HCC-preventive effect.肝细胞癌（Hepatocellular carcinoma, HCC）是全球范围内癌症相关死亡的主要诱因之一。肝硬化是已被充分证实的肝细胞癌发生风险因素，尽管肝硬化患者的肝细胞癌预防颇具挑战。通过基于临床肝细胞癌风险预测基因特征的生物信息学化合物筛选，我们鉴定出卡托普利是一种潜在的肝细胞癌化学预防剂。我们在二乙基亚硝胺（diethylnitrosamine, DEN）诱导肝硬化和肝细胞癌的大鼠模型中对该药物进行了测试，并证实了其预防肝细胞癌的作用。